|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/18/14 Bellicum Pharmaceuticals, Inc S-1 40:9.7M RR Donnelley/FA |
Document/Exhibit Description Pages Size 1: S-1 Registration Statement (General Form) HTML 1.49M 2: EX-3.1 Articles of Incorporation/Organization or By-Laws HTML 131K 3: EX-3.2 Articles of Incorporation/Organization or By-Laws HTML 32K 4: EX-3.3 Articles of Incorporation/Organization or By-Laws HTML 97K 5: EX-3.4 Articles of Incorporation/Organization or By-Laws HTML 113K 6: EX-4.2 Instrument Defining the Rights of Security Holders HTML 330K 7: EX-4.3 Instrument Defining the Rights of Security Holders HTML 55K 8: EX-4.4 Instrument Defining the Rights of Security Holders HTML 46K 9: EX-4.5 Instrument Defining the Rights of Security Holders HTML 71K 10: EX-10.1 Material Contract HTML 59K 19: EX-10.10 Material Contract HTML 93K 20: EX-10.11 Material Contract HTML 18K 21: EX-10.12 Material Contract HTML 99K 22: EX-10.13 Material Contract HTML 99K 23: EX-10.14 Material Contract HTML 14K 24: EX-10.15 Material Contract HTML 173K 25: EX-10.16 Material Contract HTML 104K 26: EX-10.17 Material Contract HTML 74K 27: EX-10.18 Material Contract HTML 110K 28: EX-10.19 Material Contract HTML 208K 11: EX-10.2 Material Contract HTML 75K 29: EX-10.20 Material Contract HTML 138K 30: EX-10.21 Material Contract HTML 359K 31: EX-10.22 Material Contract HTML 35K 32: EX-10.23 Material Contract HTML 40K 33: EX-10.24 Material Contract HTML 27K 34: EX-10.25 Material Contract HTML 45K 35: EX-10.26 Material Contract HTML 39K 36: EX-10.27 Material Contract HTML 155K 37: EX-10.28 Material Contract HTML 21K 38: EX-10.29 Material Contract HTML 17K 12: EX-10.3 Material Contract HTML 132K 13: EX-10.4 Material Contract HTML 251K 14: EX-10.5 Material Contract HTML 19K 15: EX-10.6 Material Contract HTML 99K 16: EX-10.7 Material Contract HTML 99K 17: EX-10.8 Material Contract HTML 88K 18: EX-10.9 Material Contract HTML 23K 39: EX-16.1 Letter re: Change in Certifying Accountant HTML 12K 40: EX-23.1 Consent of Experts or Counsel HTML 11K
| EX-10.11 |
Exhibit 10.11
Tom Farrell
President & Chief Executive Officer
Ken Moseley, J.D.
7913 Brightman Lane
Dear Ken:
It is my pleasure to extend the following offer of employment to you on behalf of Bellicum Pharmaceuticals, Inc. (the “Company”).
Title: Vice President of Intellectual Property & Legal Affairs; and Corporate Secretary
The position will report to the CEO, and will be based in Austin, with travel to the Company’s premises in Houston, Texas for a minimum of two working days per month.
The Job Description for this position is attached. Please keep in mind that the job description may change as the organization changes and grows. Furthermore, your title and reporting relationship may change from time to time.
Your base salary, at 50% Full Time Equivalency for a 2.5 day work week, will be paid in twice-monthly installments of $3,750.00, which is equivalent to $90,000 on an annual basis, and subject to deductions for taxes and other withholdings as required by law or agreements with the Company.
You must sign the Company’s standard non-compete and intellectual property agreements prior to your start date.
As a part time employee you will generally not be entitled to participate in the Company’s employee benefit plans and programs.
Normal and reasonable expenses, in the Company’s sole discretion, will be reimbursed on a monthly basis per Company policy and upon completion of the appropriate expense request form.
Provided that you successfully complete the Company’s standard pre-employment requirements, your start date with the Company will be December 12, 2011. Your employment with Bellicum Pharmaceuticals, Inc. is at-will and either party can terminate the relationship at any time with or without cause and with or without notice. Nothing will alter the at-will nature of this
| 6400 Fannin Street, Suite 2300 |
(713) 341-6472 |
employment relationship other than a written agreement signed by you and an authorized officer of the Company that expressly agrees to modify the at-will relationship. Nothing in this letter should be construed as a guaranty of any term of employment.
If you are in agreement with the above offer, please sign below. You acknowledge that this letter contains all of the terms and conditions of employment that you will use to make your decision and that you have not relied on any other agreements, assurances, representations or promises as the basis for your decision to accept the job as offered. This offer is in effect until December 9, 2011.
Signatures:
| /s/ Thomas J. Farrell | December 6, 2011 | |||||||
| Thomas J. Farrell, President & CEO Bellicum Pharmaceuticals, Inc. |
Date | |||||||
| /s/ Ken Moseley | ||||||||
| Ken Moseley, J.D. | Date | |||||||
| This ‘S-1’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/18/14 | None on these Dates | ||
| 12/12/11 | ||||
| 12/9/11 | ||||
| 12/8/11 | ||||
| 12/6/11 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/28/23 Bellicum Pharmaceuticals, Inc. 10-K/A 12/31/22 2:389K Workiva Inc Wde… FA01/FA 3/31/23 Bellicum Pharmaceuticals, Inc. 10-K 12/31/22 66:6.9M Workiva Inc Wde… FA01/FA 3/24/22 Bellicum Pharmaceuticals, Inc. 10-K 12/31/21 71:8.4M Workiva Inc Wde… FA01/FA 3/31/21 Bellicum Pharmaceuticals, Inc. 10-K 12/31/20 69:8.7M Workiva Inc Wde… FA01/FA 11/05/20 Bellicum Pharmaceuticals, Inc. 10-Q 9/30/20 66:9M 8/06/20 Bellicum Pharmaceuticals, Inc. S-8 8/06/20 3:148K 8/06/20 Bellicum Pharmaceuticals, Inc. 10-Q 6/30/20 60:7.1M 12/03/14 SEC UPLOAD¶ 9/13/17 1:158K Bellicum Pharmaceuticals, Inc. |